• AXT, Inc. recently reported second-quarter 2026 results showing sales of US$47.59 million and net income of US$11.13 million, alongside issuing third-quarter GAAP net income guidance of US$0.29 to US$0.31 per share and amending its bylaws to lower the shareholder meeting quorum to one-third of eligible shares.
• AXT also disclosed a long-term indium phosphide wafer substrate supply and capacity reservation agreement with Lumentum Operations, LLC, anchored by US$87,500,000 in deposits to be applied as shipment credits through 2031, signaling a multi-year customer commitment that could reshape its demand profile and production planning.
• Next, we’ll examine how the Lumentum capacity reservation and its large upfront deposits may reshape AXT’s previously outlined investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

AXT Investment Narrative Recap

To own AXT, you need to believe indium phosphide and other specialty substrates can support durable, profitable demand, particularly in AI and high-speed networking. The Lumentum capacity reservation and deposits directly touch the key near term catalyst of stronger indium phosphide pull through, while the main risk remains external export and regulatory constraints that could still disrupt shipments even with committed customers.

Among the recent announcements, the long term Lumentum agreement is most relevant here. AXT’s US$87,500,000 in deposits tied to minimum indium phosphide commitments through 2031 potentially supports better factory utilization and planning, which matters for both margin recovery and customer concentration risk. However, this contract does not remove export permit uncertainty or pricing pressure across the broader portfolio.

Yet this apparent momentum sits alongside a risk that investors should be aware of if export permits tighten further and...

AXT's narrative projects $374.9 million revenue and $141.0 million earnings by 2029.

Uncover how AXT's forecasts yield a $96.50 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, even while penciling in about US$404.3 million of revenue and US$210.0 million of earnings by 2029, and they focus more on export and technology substitution risks than on the new Lumentum deal, reminding you that views on AXT’s potential can differ sharply and that both optimistic and pessimistic narratives may need revisiting after this news.

Explore 5 other fair value estimates on AXT - why the stock might be worth as much as 41% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AXT research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.